Carotuximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Carotuximab
DrugBank Accession Number
DB06322
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Carotuximab
  • Chimeric anti-CD105 antibody
External IDs
  • C-SN6J
  • DE-122
  • TRC 105
  • TRC-105
  • TRC105

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

TRC105 is a first-in-class human chimeric monoclonal antibody that inhibits tumor growth by binding to CD105 (endoglin), a receptor over-expressed on proliferating endothelium that is required for angiogenesis (growth of new blood vessels). TRC105 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of breast and colorectal cancer. Pre-clinical data also indicate CD105 expression is increased following treatment of human cancer with anti-VEGF therapy. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both the VEGF and CD105 receptors are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero. [Traecon Pharmaceuticals Press Release]

TargetActionsOrganism
UEndoglinNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Carotuximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Carotuximab.
AducanumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Carotuximab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Carotuximab is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
YB2EWE6139
CAS number
1268714-50-6

References

General References
Not Available
Wikipedia
TRC105

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAdvanced Angiosarcoma1
2CompletedTreatmentAge - Related Macular Degeneration (AMD)1
2CompletedTreatmentCancer of the Ureter / Transitional Cell, Carcinoma / Ureteral Cancer / Ureteral Neoplasms1
2CompletedTreatmentChoriocarcinoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma (ccRCC) / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma1
2CompletedTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentHepatocellular Cancer (HCC) / Hepatocellular Carcinoma1
2CompletedTreatmentProstate Cancer1
2TerminatedTreatmentChoriocarcinoma / Epithelioid Trophoblastic Tumor / Gestational Trophoblastic Neoplasia / Trophoblastic Tumor, Placental Site1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Type ii transforming growth factor beta receptor binding
Specific Function
Major glycoprotein of vascular endothelium. Involved in the regulation of angiogenesis. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as...
Gene Name
ENG
Uniprot ID
P17813
Uniprot Name
Endoglin
Molecular Weight
70577.325 Da

Drug created on March 19, 2008 16:24 / Updated on February 21, 2021 18:52